Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 2737-2745

  Zhuang, Ming ^a,b,c,d   Shi, Qin ^a,b,c,d   Zhang, Xiuwei ^a,b,c,d   Ding, Yongbin ^a,b,c,d   Shan, Liuqun ^a,b,c,d   Shan, Xia ^a,b,c,d   Qian, Jiaqi ^a,b,c,d   Zhou, Xin ^a,b,c,d   Huang, Zebo ^a,b,c,d   Zhu, Wei ^a,b,c,d   Ding, Yin ^a,b,c,d   Cheng, Wenfang ^a,b,c,d   Liu, Ping ^a,b,c,d   Shu, Yongqian ^a,b,c,d  

^a CLINICAL MEDICAL COLLEGE OF YANGZHOU UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c THE AFFILIATED JIANGNING HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^d NANJING UNIVERSITY   (China)

Author keywords

BCL2; Cisplatin resistance; IGF1R; miR 143

Indexed keywords

CISPLATIN; IGF1R PROTEIN, HUMAN; MICRORNA; MIRN143 MICRORNA, HUMAN; SOMATOMEDIN RECEPTOR;

APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PATHOLOGY; PROTO ONCOGENE; STOMACH NEOPLASMS; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; MICRORNAS; RECEPTORS, SOMATOMEDIN; STOMACH NEOPLASMS;

EID: 84936751592     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2898-5     Document Type: Article

References (22)

1. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69–80.
2. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9–23.
3. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002;108:153–64.
4. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–54.
5. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010;46(2):298–311.
6. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncol. 2009;77(1):12–21.
7. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K, et al. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther. 2010;17(6):398–408.
8. Võsa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T. Meta-analysis of microRNA expression in lung cancer. Int J Cancer. 2013;132(12):2884–93.
9. Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007;67(13):6031–43.
10. Zhou F, Li S, Meng HM, Qi LQ, Gu L. MicroRNA and histopathological characterization of pure mucinous breast carcinoma. Cancer Biol Med. 2013;10(1):22–7.
11. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci. 2007;98(12):1914–20.
12. Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M, Enokida H. Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol. 2013;10(7):396–404.
13. Zhao DS, Chen Y, Jiang H, Lu JP, Zhang G, Geng J, et al. Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure. Cardiovasc Pathol. 2013;22(6):444–50.
14. Zhu W, Shan X, Wang TS, Shu YQ, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127(11):2520–9.
15. Ge J, Chen Z, Wu S, Chen J, Li X, Li J, et al. Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer. Digestion. 2009;80(3):148–58.
16. Hopkins A, Crowe PJ, Yang JL. Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol. 2010;136(5):639–50.
17. Murayama T, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, et al. Relation between outcomes and localisation of p-mTOR expression in gastric cancer. Br J Cancer. 2009;100(5):782–8.
18. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res. 2009;15(5):1821–9.
19. Tanida S, Mizoshita T, Ozeki K, Tsukamoto H, Kamiya T, Kataoka H, et al. Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol. 2012;2012, 862879.
20. Eckstein N, Servan K, Hildebrandt B, Politz A, von Jonquières G, Wolf-Kummeth S, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res. 2009;69(7):2996–3003.
21. Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ, Wang TY, et al. Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett. 2013;5(5):1639–42.
22. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA profiling of prostate cancer. J Cancer. 2013;4(5):350–7.